Products

Fatsiphloginum™

Fatsiphloginum™


Fatsiphloginum  exhibits anti-inflammatory [antiphlogogenic], analgetic [analgesic, antinociceptive] and antipyretic properties, reduces morbidity, hyperemia, swelling in the joints, which conditions increase in range of motions.

Сertificate of registrationСertificate of registration
Instructions for use

Instruction 

Fatsiphloginum

 

 

CHEMICAL COMPOSITION: Active components of Fatsiphloginum are: triterpene glycosides-fatsiosides.

 

PHARMACOLOGICAL FEATURES:  Fatsiphloginum  exhibits anti-inflammatory [antiphlogogenic], analgetic [analgesic, antinociceptive] and antipyretic properties, reduces morbidity, hyperemia, swelling in the joints, which conditions increase in range of motions.

Analgetic and antipyretic action is revealed 1,5-2 hours after administration of the drug. As for reduction in occurrence of inflammation, namely, in the joints, after the first or the second week of treatment.

 

THERAPEUTIC INDICATIONS: rheumatoid joint inflammation, osteoarthritis,  ankylosing [rheumatoid] spondylitis, rheumatism, osteoarthritis deformans, reactive synovitis, osteochondrosis, tendinitis, tendovaginitis,  gout, pain in spine, myalgia, traumatic inflammation of soft tissues and support-motor [locomotor] apparatus.

 

DOSAGE AND DIRECTIONS FOR USE: one-time and daily dosage is established individually, in adults25-30 mg (0,0025-0,05g) Fatsiphloginum is swallowed  three-four  times daily, after meal, daily dosage up to 200 mg (0.2g).

 

SIDE EFFECTS AND SPECIAL PRECAUTIONS: unlike other nonsteroid anti-inflammatory medicaments (NSAID), Fatsiphloginum very rarely causes gastric irritation, expressed as moderate gastralgia, feelings of discomfort in the epigastric region, which is no reason for treatment cessation – reduction in dosage and observance of the diet, occurrence of gastric irritation vanishes.

In single cases Fatsiphloginum may cause increase in blood [arterial] pressure, nettle-rash type skin efflorescence, provided that such symptoms occur , Fatsiphloginum treatment should be ceased.

 

CONTRAINDICATION: Fatsiphloginum is contraindicated in patients with acute erosive- ulcer  lesions of gastrointestinal tract,  arterial hypertension, bronchial asthma (“aspirin asthma”), pregnancy during the last trimester, heart failure, renal insufficiency or hepatic insufficiency.

 

PRESENTATION: 50 mg tabletss – blisters # 60

 

STORAGE INSTRUCTIONS: Store in a cool and dry place. Protect from light.

 

SHELF LIFE:  4 years.